The study also presented the first external validation and use in patients with early RA of six proposed screening strategies ...

C HICAGO -- People who died with systemic lupus erythematosus (SLE) were far more likely than car crash victims to have ...

The Quebec Society of Vascular Sciences (QSVS) is launching a new conversational AI-powered tool, AmelIA, to its Vascular Health Portal, This initiative, developed in partnership with Boehringer ...

Mergers and acquisitions are not just for Big Pharma. A new report from Leerink Partners takes a stab at identifying the ...

In the treatment of cardiometabolic disease, much has changed in the past 20 years, especially with the emergence of novel ...

An individual patient-level meta-analysis shows that tenecteplase, a next-generation thrombolytic, is at least as effective ...

As pharmaphorum reported during ESMO 2025, fresh from a return to oncology with the FDA approval of zongertinib as a ...

Boehringer Ingelheim, which has so far inked at least five hefty partnerships—including its latest one with South Korea’s ...

After charting several related moves earlier this year, Boehringer Ingelheim is returning to the antibody-drug conjugate well ...

Boehringer Ingelheim and AimedBio, a biotechnology company specializing in the development of antibody-based therapeutics, ...

Boehringer Ingelheim, a leading research-driven biopharmaceutical company, hosted its CRM Summit on 10th–11th October at Conrad Abu Dhabi Etihad Towers.The event brought together more than 300 ...

According to Boehringer, Hernexeos achieved a 77% objective response rate (OOR) in a cohort of previously untreated HER2+ ...